Cargando…

[(18)F]AlF-NOTA-ADH-1: A new PET molecular radiotracer for imaging of N-cadherin-positive tumors

BACKGROUND: The cell adhesion molecule (CAM) N-cadherin has become an important target for tumor therapy. The N-cadherin antagonist, ADH-1, exerts significant antitumor activity against N-cadherin-expressing cancers. METHODS: In this study, [(18)F]AlF-NOTA-ADH-1 was radiosynthesized. An in vitro cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhenfeng, Wen, Guanghua, Huang, Yuqiao, Dong, Yanzhao, Wang, Zewei, Alhaskawi, Ahmad, Zhang, Shuyi, Wang, GuoLin, Ye, Qianni, Zhou, Haiying, Lu, Hui, Dong, Mengjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239968/
https://www.ncbi.nlm.nih.gov/pubmed/37284201
http://dx.doi.org/10.3389/fonc.2023.1126721
_version_ 1785053615079030784
author Liu, Zhenfeng
Wen, Guanghua
Huang, Yuqiao
Dong, Yanzhao
Wang, Zewei
Alhaskawi, Ahmad
Zhang, Shuyi
Wang, GuoLin
Ye, Qianni
Zhou, Haiying
Lu, Hui
Dong, Mengjie
author_facet Liu, Zhenfeng
Wen, Guanghua
Huang, Yuqiao
Dong, Yanzhao
Wang, Zewei
Alhaskawi, Ahmad
Zhang, Shuyi
Wang, GuoLin
Ye, Qianni
Zhou, Haiying
Lu, Hui
Dong, Mengjie
author_sort Liu, Zhenfeng
collection PubMed
description BACKGROUND: The cell adhesion molecule (CAM) N-cadherin has become an important target for tumor therapy. The N-cadherin antagonist, ADH-1, exerts significant antitumor activity against N-cadherin-expressing cancers. METHODS: In this study, [(18)F]AlF-NOTA-ADH-1 was radiosynthesized. An in vitro cell binding test was performed, and the biodistribution and micro-PET imaging of the probe targeting N-cadherin were also studied in vivo. RESULTS: Radiolabeling of ADH-1 with [(18)F]AlF achieved a yield of up to 30% (not decay-corrected) with a radiochemical purity of >97%. The cell uptake study showed that Cy3-ADH-1 binds to SW480 cells but weakly binds to BXPC3 cells in the same concentration range. The biodistribution results demonstrated that [(18)F]AlF-NOTA-ADH-1 had a good tumor/muscle ratio (8.70±2.68) in patient-derived xenograft (PDX) tumor xenografts but a lower tumor/muscle ratio (1.91±0.69) in SW480 tumor xenografts and lowest tumor/muscle ratio (0.96±0.32) in BXPC3 tumor xenografts at 1 h post-injection (p.i.) These findings were in accordance with the immunohistochemistry results. The micro PET imaging results revealed good [18F]AlF-NOTA-ADH-1 tumor uptake in pancreatic cancer PDX xenografts with strong positive N-calcium expression, while lower tumor uptake in SW480 xenografts with positive expression of N-cadherin, and significantly lower tumor uptake in BXPC3 xenografts with low expression of N-cadherin, which was consistent with the biodistribution and immunohistochemistry results. The N-cadherin-specific binding of [18F]AlF-NOTA-ADH-1 was further verified by a blocking experiment involving coinjection of a non radiolabeled ADH-1 peptide, resulting in a significant reduction in tumor uptake in PDX xenografts and SW480 tumor. CONCLUSION: [(18)F]AlF-NOTA-ADH-1 was successfully radiosynthesized, and Cy3-ADH-1 showed favorable N-cadherin-specific targeting ability by in vitro data. The biodistribution and microPET imaging of the probe further showed that [18F]AlF-NOTA-ADH-1 could discern different expressions of N-cadherin in tumors. Collectively, the findings demonstrated the potential of [(18)F]AlF-NOTA-ADH-1 as a PET imaging probe for non-invasive evaluation of the N-cadherin expression in tumors.
format Online
Article
Text
id pubmed-10239968
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102399682023-06-06 [(18)F]AlF-NOTA-ADH-1: A new PET molecular radiotracer for imaging of N-cadherin-positive tumors Liu, Zhenfeng Wen, Guanghua Huang, Yuqiao Dong, Yanzhao Wang, Zewei Alhaskawi, Ahmad Zhang, Shuyi Wang, GuoLin Ye, Qianni Zhou, Haiying Lu, Hui Dong, Mengjie Front Oncol Oncology BACKGROUND: The cell adhesion molecule (CAM) N-cadherin has become an important target for tumor therapy. The N-cadherin antagonist, ADH-1, exerts significant antitumor activity against N-cadherin-expressing cancers. METHODS: In this study, [(18)F]AlF-NOTA-ADH-1 was radiosynthesized. An in vitro cell binding test was performed, and the biodistribution and micro-PET imaging of the probe targeting N-cadherin were also studied in vivo. RESULTS: Radiolabeling of ADH-1 with [(18)F]AlF achieved a yield of up to 30% (not decay-corrected) with a radiochemical purity of >97%. The cell uptake study showed that Cy3-ADH-1 binds to SW480 cells but weakly binds to BXPC3 cells in the same concentration range. The biodistribution results demonstrated that [(18)F]AlF-NOTA-ADH-1 had a good tumor/muscle ratio (8.70±2.68) in patient-derived xenograft (PDX) tumor xenografts but a lower tumor/muscle ratio (1.91±0.69) in SW480 tumor xenografts and lowest tumor/muscle ratio (0.96±0.32) in BXPC3 tumor xenografts at 1 h post-injection (p.i.) These findings were in accordance with the immunohistochemistry results. The micro PET imaging results revealed good [18F]AlF-NOTA-ADH-1 tumor uptake in pancreatic cancer PDX xenografts with strong positive N-calcium expression, while lower tumor uptake in SW480 xenografts with positive expression of N-cadherin, and significantly lower tumor uptake in BXPC3 xenografts with low expression of N-cadherin, which was consistent with the biodistribution and immunohistochemistry results. The N-cadherin-specific binding of [18F]AlF-NOTA-ADH-1 was further verified by a blocking experiment involving coinjection of a non radiolabeled ADH-1 peptide, resulting in a significant reduction in tumor uptake in PDX xenografts and SW480 tumor. CONCLUSION: [(18)F]AlF-NOTA-ADH-1 was successfully radiosynthesized, and Cy3-ADH-1 showed favorable N-cadherin-specific targeting ability by in vitro data. The biodistribution and microPET imaging of the probe further showed that [18F]AlF-NOTA-ADH-1 could discern different expressions of N-cadherin in tumors. Collectively, the findings demonstrated the potential of [(18)F]AlF-NOTA-ADH-1 as a PET imaging probe for non-invasive evaluation of the N-cadherin expression in tumors. Frontiers Media S.A. 2023-05-22 /pmc/articles/PMC10239968/ /pubmed/37284201 http://dx.doi.org/10.3389/fonc.2023.1126721 Text en Copyright © 2023 Liu, Wen, Huang, Dong, Wang, Alhaskawi, Zhang, Wang, Ye, Zhou, Lu and Dong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Zhenfeng
Wen, Guanghua
Huang, Yuqiao
Dong, Yanzhao
Wang, Zewei
Alhaskawi, Ahmad
Zhang, Shuyi
Wang, GuoLin
Ye, Qianni
Zhou, Haiying
Lu, Hui
Dong, Mengjie
[(18)F]AlF-NOTA-ADH-1: A new PET molecular radiotracer for imaging of N-cadherin-positive tumors
title [(18)F]AlF-NOTA-ADH-1: A new PET molecular radiotracer for imaging of N-cadherin-positive tumors
title_full [(18)F]AlF-NOTA-ADH-1: A new PET molecular radiotracer for imaging of N-cadherin-positive tumors
title_fullStr [(18)F]AlF-NOTA-ADH-1: A new PET molecular radiotracer for imaging of N-cadherin-positive tumors
title_full_unstemmed [(18)F]AlF-NOTA-ADH-1: A new PET molecular radiotracer for imaging of N-cadherin-positive tumors
title_short [(18)F]AlF-NOTA-ADH-1: A new PET molecular radiotracer for imaging of N-cadherin-positive tumors
title_sort [(18)f]alf-nota-adh-1: a new pet molecular radiotracer for imaging of n-cadherin-positive tumors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239968/
https://www.ncbi.nlm.nih.gov/pubmed/37284201
http://dx.doi.org/10.3389/fonc.2023.1126721
work_keys_str_mv AT liuzhenfeng 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT wenguanghua 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT huangyuqiao 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT dongyanzhao 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT wangzewei 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT alhaskawiahmad 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT zhangshuyi 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT wangguolin 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT yeqianni 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT zhouhaiying 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT luhui 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors
AT dongmengjie 18falfnotaadh1anewpetmolecularradiotracerforimagingofncadherinpositivetumors